"FDA Grants Breakthrough Designation to Single Dose LSD Therapy for Anxiety"
A new study conducted by biopharmaceutical company MindMed has found that a single dose of MM120, a form of LSD, can provide lasting relief to patients suffering from generalized anxiety disorder (GAD), with a 48% rate of remission after 12 weeks and about 65% of patients seeing improvements within three months. The drug will need to go through the standard FDA approval process and will soon enter phase III trials.